NCT06626646Completed
Vascular Regenerative Cell Exhaustion in Adults With Peripheral Artery Disease (PAD-VRCE)
Vascular Regenerative Cell Exhaustion in Adults With Peripheral Artery Disease
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
PAD-VRCE is an observational, cross-sectional, two arm study aimed at determining if the presence of peripheral artery disease (PAD) can influence the number of circulating regenerative cells in blood. From peripheral blood samples, circulating progenitor cell content will be assessed via flow cytometry and compared between individuals with PAD and individuals without PAD. Ultimately, this study plans to evaluate the relationship between PAD, vascular regenerative cell exhaustion and overall cardiovascular health.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 2 Oct 2024
- Start date
- 5 Oct 2024
- Primary completion date
- 5 Dec 2024
- Lead sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
- Diseases
- Type 2 diabetes
- NCT number
- NCT06626646
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 5 Oct 2024 to the primary completion date, 5 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.
- On oral steroid therapy (e.g. prednisone or other corticosteroids) or other immunosuppressive agents (e.g. methotrexate).
Other illness
- Any life-threatening disease expected to result in death within two years.
- Uncontrolled hypertension.
- New York Heart Association Class IV heart failure.
- Active liver disease or liver dysfunction.
- Active kidney disease or kidney dysfunction.
- History of hemorrhagic stroke or other major bleeding disorder.
- Active infectious disease requiring systemic antibiotic or anti-viral agents.
- Known acquired immunodeficiency syndrome, such as Human Immunodeficiency Virus.
- Treated autoimmune disorders
Lab values
- White blood cell count of ≥15x10\^9/L.
Other
- Unable or unwilling to provide written informed consent or to provide a peripheral blood sample.
Who the study is looking for
- Adults ≥18 and ≤80 years of age who meet either of the following criteria:
- Clinically significant/symptomatic PAD (defined as symptomatic claudication with and an ankle brachial index of less than 0.85).
- No history of PAD.
- Willing and able to provide written informed consent and comply with study procedures.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| North York Diagnostic and Cardiac Centre Coordinator of this site? Confirm its status | North York | Canada | Unknown status |
| Diagnostic Assessment Centre Coordinator of this site? Confirm its status | Scarborough Village | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.